Show simple item record

dc.contributor.authorTorgauten, Hilde Marie
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorWergeland, Stig
dc.contributor.authorBø, Lars
dc.contributor.authorAarseth, Jan Harald
dc.contributor.authorTorkildsen, Øivind
dc.date.accessioned2021-08-09T08:55:08Z
dc.date.available2021-08-09T08:55:08Z
dc.date.created2021-04-14T12:27:16Z
dc.date.issued2021-01-31
dc.identifier.issn2055-2173
dc.identifier.urihttps://hdl.handle.net/11250/2766925
dc.description.abstractBackground Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy escalation. Objective To investigate the safety and efficacy of off-label treatment with rituximab in an MS-cohort of predominantly de novo patients or as therapy escalation. Methods We retrieved safety and efficacy data from the Norwegian MS-registry and biobank for all MS-patients treated with rituximab at Haukeland University Hospital, Bergen, Norway, during a four year period. Results In the 365 MS-patients (320 relapsing-remitting MS (RRMS), 23 secondary progressive MS (SPMS), and 22 primary progressive MS (PPMS)), the overall annualized relapse rate (ARR) was 0.03 and annualized drug discontinuation rate (ADDR) was 0.05. NEDA-3 was achived in 79% of patients with available data (n=351). Sixty-one patients experienced infusion-related adverse events of which two were serious (CTCAE grade 3–4). Eighteen patients experienced serious non-infusion related adverse events, of which 16 were infections. Infections (n = 34; 9.3%, CTCAE grade 2-5), hypogammaglobulinemia (n = 19, 5.2%) and neutropenia (n = 16; 4.4%) were the most common non-infusion-related adverse events. Conclusion Rituximab was a safe and highly efficient disease modifying therapy in this cohort of MS-patients; however, infections and neutropenia need to be monitored.en_US
dc.language.isoengen_US
dc.publisherSAGEen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSafety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s), 2021en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1177/2055217320973049
dc.identifier.cristin1903993
dc.source.journalMultiple Sclerosis Journal, Experimental, Translational and Clinicalen_US
dc.source.pagenumber1-10en_US
dc.identifier.citationMultiple Sclerosis Journal, Experimental, Translational and Clinical. 2021, 7 (1), 1-10.en_US
dc.source.volume7en_US
dc.source.issue1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal